112 related articles for article (PubMed ID: 22801957)
21. Practical management of imatinib in gastrointestinal stromal tumors.
Barnes T; Reinke D
Clin J Oncol Nurs; 2011 Oct; 15(5):533-45. PubMed ID: 21951740
[TBL] [Abstract][Full Text] [Related]
22. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Láng I; Hitre E
Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
[TBL] [Abstract][Full Text] [Related]
23. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
Hatoum HT; Lin SJ; Sasane M; Trent JC
Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625
[TBL] [Abstract][Full Text] [Related]
25. [A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate].
Nakatani K; Tanabe S; Nishimura K; Shimoda T; Azuma M; Katada C; Sasaki T; Higuchi K; Koizumi W; Saigenji K
Gan To Kagaku Ryoho; 2006 Jul; 33(7):997-1000. PubMed ID: 16835496
[TBL] [Abstract][Full Text] [Related]
26. Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Prescrire Int; 2011 Feb; 20(113):38. PubMed ID: 21488587
[No Abstract] [Full Text] [Related]
27. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
[TBL] [Abstract][Full Text] [Related]
28. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
Yeh CN; Fu CJ; Yen TC; Chiang KC; Jan YY; Chen MF
J Clin Oncol; 2013 Jun; 31(16):e248-50. PubMed ID: 23569321
[No Abstract] [Full Text] [Related]
29. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
[TBL] [Abstract][Full Text] [Related]
30. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Izquierdo ME; Bonastre MT
Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
[TBL] [Abstract][Full Text] [Related]
31. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
32. Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors.
Blanke CD
JAMA; 2012 Mar; 307(12):1312-4. PubMed ID: 22453573
[No Abstract] [Full Text] [Related]
33. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
Gronchi A; Blay JY; Trent JC
Cancer; 2010 Apr; 116(8):1847-58. PubMed ID: 20166214
[TBL] [Abstract][Full Text] [Related]
34. Intervention in gastrointestinal stromal tumour with a high risk of malignancy and associated with thalassaemia minor.
Pericay Pijaume C; Saigi Grau E
Anticancer Drugs; 2012 Jun; 23 Suppl():S13-4. PubMed ID: 22614104
[TBL] [Abstract][Full Text] [Related]
35. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
36. Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
Blay JY; Adenis A; Ray-Coquard I; Cassier PA; Le Cesne A
Curr Opin Oncol; 2009 Jul; 21(4):360-6. PubMed ID: 19509502
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
Bümming P; Andersson J; Meis-Kindblom JM; Klingenstierna H; Engström K; Stierner U; Wängberg B; Jansson S; Ahlman H; Kindblom LG; Nilsson B
Br J Cancer; 2003 Aug; 89(3):460-4. PubMed ID: 12888812
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?
Hohenberger P
Lancet; 2009 Mar; 373(9669):1058-60. PubMed ID: 19303138
[No Abstract] [Full Text] [Related]
40. Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs).
Yang P; Chen B; Zhou Y; Wu XT
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):484-90. PubMed ID: 22889747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
